Literature DB >> 16563867

Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections.

Stuart E Turvey1, Thomas R Hawn.   

Abstract

Recent years have seen a dramatic improvement in our understanding of the role of innate immunity, and particularly Toll-like receptor (TLR) signaling, in human host defense. Appreciation of how defects in human TLR signaling enhance susceptibility to infection began with the identification of patients with monogenic immunodeficiencies, such as hypohydrotic ectodermal dysplasia with immunodeficiency and IRAK4 deficiency. Empowered by technological advances in genotyping and bioinformatics, we are now beginning to appreciate how common genetic variation in the genes controlling the innate immune response alters infectious susceptibility in a subtle but specific fashion. This review highlights the mechanisms of infectious susceptibility that result from complex interactions between the genetically variable host and microbe and explores how this new knowledge may ultimately translate into better care for our patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563867     DOI: 10.1016/j.clim.2006.02.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  22 in total

1.  Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation.

Authors:  Darren Blimkie; Edgardo S Fortuno; Howard Yan; Patricia Cho; Kevin Ho; Stuart E Turvey; Arnaud Marchant; Stanislas Goriely; Tobias R Kollmann
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

Review 2.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

3.  Polychromatic flow cytometric high-throughput assay to analyze the innate immune response to Toll-like receptor stimulation.

Authors:  Kirstin Jansen; Darren Blimkie; Jeff Furlong; Adeline Hajjar; Annie Rein-Weston; Juliet Crabtree; Brian Reikie; Christopher Wilson; Tobias Kollmann
Journal:  J Immunol Methods       Date:  2008-05-16       Impact factor: 2.303

Review 4.  C-type lectins with a sweet spot for Mycobacterium tuberculosis.

Authors:  G Lugo-Villarino; D Hudrisier; A Tanne; O Neyrolles
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-03

5.  Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis C Virus Infection and Hepatic Fibrosis in Egyptian Patients.

Authors:  Rania A Zayed; Dalia Omran; Doha A Mokhtar; Zinab Zakaria; Sameera Ezzat; Mohamed A Soliman; Lamiaa Mobarak; Hossam El-Sweesy; Ghada Emam
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

6.  Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes.

Authors:  D Han; X Cai; J Wen; D Matheson; J S Skyler; N S Kenyon; Z Chen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.

Authors:  Reuben Ramphal; Viviane Balloy; Jeevan Jyot; Amrisha Verma; Mustapha Si-Tahar; Michel Chignard
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.

Authors:  Renée N Douville; Yuriy Lissitsyn; Aaron F Hirschfeld; Allan B Becker; Anita L Kozyrskyj; Joel Liem; Nathalie Bastien; Yan Li; Rachel E Victor; Mehtab Sekhon; Stuart E Turvey; Kent T HayGlass
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 9.  Innate immunity.

Authors:  Stuart E Turvey; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2009-11-24       Impact factor: 10.793

Review 10.  The role of Toll-like receptor signaling in human immunodeficiencies.

Authors:  Hanna Suhir; Amos Etzioni
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.